Technology
Health
Biotechnology

Erytech Pharma

$7.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.42%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Erytech Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Erytech Pharma S.A. American Depositary Shares, also called Erytech Pharma, is a biopharmaceutical company, which develops medical products. Read More It engages in developing and producing therapeutic products for cancer and orphan diseases. The company was founded by Pierre-Olivier Goineau and Yann Godfrin on November 22, 2004 and is headquartered in Lyon, France.

Employees
172
Headquarters
Lyon, Rhone-Alpes
Founded
2004
Market Cap
127.36M
Price-Earnings Ratio
Dividend Yield
Average Volume
2.16K
High Today
$7.32
Low Today
$7.07
Open Price
$7.32
Volume
101.00
52 Week High
$19.76
52 Week Low
$5.45

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Cancer Prevention
Pharmaceutical
2016 IPO

News

Seeking AlphaMay 13

Erytech Pharma on go with late-stage study of eryaspase in pancreatic cancer

The FDA has signed off on ERYTECH Pharma's (NASDAQ:ERYP) IND for a Phase 3 clinical trial evaluating lead candidate eryaspase, an enzyme called L-asparaginase encapsulated in donor-derived red blood cells, in second-line pancreatic cancer.

6
Seeking AlphaMay 13

ERYTECH Pharma S.A. CEO Gil Beyen on Q1 2019 Results - Earnings Call Transcript

ERYTECH Pharma S.A. (NASDAQ:ERYP) Q1 2019 Results Earnings Conference Call May 7, 2019 8:30 AM ET Company Participants Gil Beyen - Chief Executive Officer Eric Soyer - Chief Financial Officer and Chief Operating Officer Iman El Hariry - Chief Medical Officer Conference Call Participants Boris Peaker - Cowen and Company Anastasia Karpova - Kempen Philippa Gardner - Jefferies Operator Thank you, Michelle. Good morning. I'm in Boston right now. So, people on the side. And good afternoon in Europe. We...

3
Markets InsiderMay 6

ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019

TRYbeCA1, pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, actively enrolling patients Construction of new manufacturing site in Princeton and extension of Lyon facility completed Cash position of €110.5 million ($124 million) at the end of March – Cash utilization guidance confirmed LYON, France, May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP),a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug ...

4

Earnings

-$0.73
-$0.63
-$0.53
-$0.43
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 12, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.